Brief Title
Evaluation of Thiol Disulfide Balance in Stage 1 Endometrium Cancer
Official Title
Assessment of Thiol Disulfide Balance in Early Stage Endometrium Cancer
Brief Summary
The purpose of this study is to investigate thiol-disulfide balance in early stage
endometrium cancer patients.
Detailed Description
To date various oxidative stress paramaters were studied in patients with endometrial cancer,
however dynamic thiol disulfide hemostasis has not been previously investigated.
The thiol-disulfide balance in the circulation will be measured by the automated system
created by Erel & Neselioglu(1).
References
1- Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin
Biochem 2014;47:326-32. doi:10.1016/j.clinbiochem.2014.09.026.
Study Type
Observational
Primary Outcome
serum native thiol level
Secondary Outcome
total antioxidant capacity (TAC)
Condition
Endometrium Cancer
Intervention
Disulphide(μmol/L)
Study Arms / Comparison Groups
Endometrium cancer
Description: stage I endometrium cancer n=57
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Diagnostic Test
Estimated Enrollment
117
Start Date
August 1, 2018
Completion Date
November 15, 2019
Primary Completion Date
October 31, 2019
Eligibility Criteria
Inclusion Criteria:
• Histopathologically confirmed diagnosis of stage I endometrium cancer
Exclusion Criteria:
- pulmonary disease
- pulmonary hypertension
- cardiac dysfunction
- renal dysfunction
- liver disease
- chronic ishemia
- systemic inflammation
- concomitant malignancy
- patients who use vitamin A,C or E (antioxidant vitamins)
- patients who use smoke
- patients who use drink alcohol
- patients who use addictive for any drug
Gender
Female
Ages
18 Years - N/A
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Burak Sezgin, ,
Location Countries
Turkey
Location Countries
Turkey
Administrative Informations
NCT ID
NCT04175067
Organization ID
09/08/2018-13-9
Responsible Party
Principal Investigator
Study Sponsor
Muğla Sıtkı Koçman University
Study Sponsor
Burak Sezgin, Principal Investigator, Mugla Sıtkı Kocman University Faculty of Medicine
Verification Date
November 2019